Please note that the ANZCTR website will be unavailable from 3:00-3:30pm this Thursday the 25th of October. At this time the IPD sharing statement and summary results sections will be added to the ANZCTR form in order to comply with the updated WHO Trial Registration Data Set.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Trial ID
ACTRN12605000073606
Ethics application status
Approved
Date submitted
4/08/2005
Date registered
4/08/2005
Date last updated
29/07/2008
Type of registration
Retrospectively registered

Titles & IDs
Public title
A non-randomised trial evaluating in-field control following the addition of involved-field radiotherapy to transplantation for patients with Hodgkins Disease and non-Hodgkins Lymphoma: An ALLG/TROG Prospective Multicentre Study
Scientific title
A non-randomised trial evaluating in-field control following the addition of involved-field radiotherapy to transplantation for patients with Hodgkin's Disease and non-Hodgkin's Lymphoma: An ALLG/TROG Prospective Multicentre Study
Secondary ID [1] 100 0
Australasian Leukaemia and Lymphoma Group (ALLG): ALLG HDNHL4
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hodgkin's disease 147 0
Non-Hodgkins lymphoma 148 0
Condition category
Condition code
Cancer 166 166 0 0
Hodgkin's
Cancer 167 167 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
A prospective non randomised trial evaluating the rate of in-field failure in patients having protocol radiotherapy with transplantation for Hodgkin's and non-Hodgkin's lymphoma.
Intervention code [1] 116 0
Treatment: Other
Comparator / control treatment
Control group
Uncontrolled

Outcomes
Primary outcome [1] 206 0
Determine the cumulative incidence of progression in irradiated pre-transplant sites of failure
Timepoint [1] 206 0
3 years following commencement of treatment
Secondary outcome [1] 467 0
1. Determine the cumulative incidence of progression outside pre-transplant sites of failure
Timepoint [1] 467 0
3 years following commencement of treatment.
Secondary outcome [2] 468 0
2. Determine overall progression free survival and time to progression
Timepoint [2] 468 0
At 3 years.
Secondary outcome [3] 469 0
3. Assess selected toxicities attributable to protocol RT
Timepoint [3] 469 0
Secondary outcome [4] 470 0
Determine overall survival
Timepoint [4] 470 0
At 3 years.
Secondary outcome [5] 471 0
5. Document the time to haematological recovery from post-transplant RT-induced cytopaenia, which occurs after a progenitor cell infusion, and the duration of recovery.
Timepoint [5] 471 0
Secondary outcome [6] 472 0
6. Assess the prognostic significance of conventional and functional imaging response to cytoreduction chemotherapy.
Timepoint [6] 472 0

Eligibility
Key inclusion criteria
1. Histological diagnosis of HD or NHL other than follicular grade I-II, small lymphocytic and marginal zone lymphoma; 2. Failure to achieve CR with first line therapy, or relapse after CR to first line therapy*; 3. No more than 2 lines (ie regimens) of cytoreduction chemotherapy; 4. At least a 50% reduction in the sum of products of tumour diameters following cytoreduction chemotherapy (NHL only); 5. Sites of failure confined to lymph nodes, spleen, Waldeyer's ring and limited extra-nodal sites (solitary soft tissue deposit or single bone or one kidney or extension from nodal site into contiguous lung, pleura, pericardium, neural structure or liver) that can be treated within a tolerable RT field (histological evidence of bone marrow relapse is also permissible); 6. Sites of failure are adequately documented for RT planning; 7. The patient is planned to undergo autologous transplantation; 8. Confirmation of adequate progenitor cell harvest (> 2x106 CD34+ve cells/Kg); 9. The patient's age is at least 18; 10. The patient's ECOG performance status is two or less; 11. The patient has provided written informed consent.
Minimum age
18 Years
Maximum age
Not stated
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Prior dose-limiting RT to site requiring RT; 2. Planned TBI-based conditioning; 3. Sites of failure include haematogenous involvement of lung or liver parenchyma, brain or both kidneys; 4. Sites of failure include diffuse or disseminated involvement of pleura/pericardium, spinal cord/spinal meninges, bone or skin/soft tissue; 5. Any condition which in the opinion of the investigators puts patients at undue risk of RT toxicity; 6. Women who are pregnant or breast feeding 7. Patients who are not using adequate contraception (if relevant).

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint(s)
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 219 0
Other Collaborative groups
Name [1] 219 0
Royal Australian and New Zealand College of Radiologists
Address [1] 219 0
Country [1] 219 0
Australia
Funding source category [2] 220 0
Charities/Societies/Foundations
Name [2] 220 0
Peter MacCallum Cancer Centre Division of Radiation Oncology
Address [2] 220 0
Country [2] 220 0
Australia
Funding source category [3] 221 0
Commercial sector/Industry
Name [3] 221 0
Amgen Australia
Address [3] 221 0
Country [3] 221 0
Australia
Funding source category [4] 222 0
Commercial sector/Industry
Name [4] 222 0
Baxter Healthcare Australia
Address [4] 222 0
Country [4] 222 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Australasian Leukaemia and Lymphoma Group
Address
Country
Australia
Secondary sponsor category [1] 165 0
None
Name [1] 165 0
nil
Address [1] 165 0
Country [1] 165 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 1014 0
Royal Adelaide
Ethics committee address [1] 1014 0
Ethics committee country [1] 1014 0
Australia
Date submitted for ethics approval [1] 1014 0
Approval date [1] 1014 0
Ethics approval number [1] 1014 0
Ethics committee name [2] 1015 0
Alfred
Ethics committee address [2] 1015 0
Ethics committee country [2] 1015 0
Australia
Date submitted for ethics approval [2] 1015 0
Approval date [2] 1015 0
Ethics approval number [2] 1015 0
Ethics committee name [3] 1016 0
Christchurch
Ethics committee address [3] 1016 0
Ethics committee country [3] 1016 0
New Zealand
Date submitted for ethics approval [3] 1016 0
Approval date [3] 1016 0
Ethics approval number [3] 1016 0
Ethics committee name [4] 1017 0
Geelong
Ethics committee address [4] 1017 0
Ethics committee country [4] 1017 0
Australia
Date submitted for ethics approval [4] 1017 0
Approval date [4] 1017 0
Ethics approval number [4] 1017 0
Ethics committee name [5] 1018 0
Mater Newcastle
Ethics committee address [5] 1018 0
Ethics committee country [5] 1018 0
Australia
Date submitted for ethics approval [5] 1018 0
Approval date [5] 1018 0
Ethics approval number [5] 1018 0
Ethics committee name [6] 1019 0
Peter MacCallum
Ethics committee address [6] 1019 0
Ethics committee country [6] 1019 0
Australia
Date submitted for ethics approval [6] 1019 0
Approval date [6] 1019 0
Ethics approval number [6] 1019 0
Ethics committee name [7] 1020 0
Royal Prince Alfred
Ethics committee address [7] 1020 0
Ethics committee country [7] 1020 0
Australia
Date submitted for ethics approval [7] 1020 0
Approval date [7] 1020 0
Ethics approval number [7] 1020 0
Ethics committee name [8] 1021 0
St Vincent's Melbourne
Ethics committee address [8] 1021 0
Ethics committee country [8] 1021 0
Australia
Date submitted for ethics approval [8] 1021 0
Approval date [8] 1021 0
Ethics approval number [8] 1021 0
Ethics committee name [9] 1022 0
Westmead
Ethics committee address [9] 1022 0
Ethics committee country [9] 1022 0
Australia
Date submitted for ethics approval [9] 1022 0
Approval date [9] 1022 0
Ethics approval number [9] 1022 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 35379 0
Address 35379 0
Country 35379 0
Phone 35379 0
Fax 35379 0
Email 35379 0
Contact person for public queries
Name 9305 0
Dr Andrew Wirth
Address 9305 0
Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002
Country 9305 0
Australia
Phone 9305 0
+61 3 96561111
Fax 9305 0
+61 3 96561424
Email 9305 0
email andrew.wirth@petermac.org
Contact person for scientific queries
Name 233 0
Dr Andrew Wirth
Address 233 0
Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002
Country 233 0
Australia
Phone 233 0
+61 3 96561111
Fax 233 0
+61 3 96561424
Email 233 0
email andrew.wirth@petermac.org